Paul R. Delmar

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 48 publications

Stride-level measurement of gait as an early sensitive marker of disability progression in ambulatory patients with multiple sclerosis.

Stride-level measurement of gait as an early sensitive marker of disability progression in ambulatory patients with multiple sclerosis.

Journal: EClinicalMedicine

Published: September 26, 2025

Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU Trial.

Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU Trial.

Journal: medRxiv : the preprint server for health sciences

Published: February 20, 2025

Long-term safety of gantenerumab in participants with Alzheimer's disease: A phase III, open-label extension study (SCarlet RoAD).

Long-term safety of gantenerumab in participants with Alzheimer's disease: A phase III, open-label extension study (SCarlet RoAD).

Journal: Journal of Alzheimer's disease : JAD

Published: December 17, 2024

Japanese participant data from three gantenerumab trials in early Alzheimer's disease.

Japanese participant data from three gantenerumab trials in early Alzheimer's disease.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

Published: September 25, 2024

Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial.

Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial.

Journal: The Lancet. Neurology

Published: September 05, 2024

Long-Term Safety of Gantenerumab in Participants with Alzheimer's Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD).

Long-Term Safety of Gantenerumab in Participants with Alzheimer's Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD).

Journal: Journal of Alzheimer's disease : JAD

Published: August 23, 2024

Biomarker treatment effects in two phase 3 trials of gantenerumab.

Biomarker treatment effects in two phase 3 trials of gantenerumab.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

Published: July 03, 2024

Care partner-informed meaningful change thresholds for the Clinical Dementia Rating-Sum of Boxes for trials of early Alzheimer's disease.

Care partner-informed meaningful change thresholds for the Clinical Dementia Rating-Sum of Boxes for trials of early Alzheimer's disease.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

Published: February 08, 2024

Statistical considerations when estimating time-saving treatment effects in Alzheimer's disease clinical trials.

Statistical considerations when estimating time-saving treatment effects in Alzheimer's disease clinical trials.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

Published: January 30, 2024

Rejoinder to the letter: "Standard and reference-based conditional mean imputation: Regulators and trial statisticians be aware!"

Rejoinder to the letter: "Standard and reference-based conditional mean imputation: Regulators and trial statisticians be aware!"

Journal: Pharmaceutical statistics

Published: January 26, 2024

Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.

Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.

Journal: The New England journal of medicine

Published: November 15, 2023

Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease.

Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

Published: September 20, 2023

Showing 1-12 of 48

Last Updated: 09/26/2026